PriceTargets.com logo

Alnylam Pharmaceuticals - ALNY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $315.58
  • Forecasted Upside: 34.54%
  • Number of Analysts: 26
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 21 Buy Ratings
  • 0 Strong Buy Ratings
$234.56 As of 04/17/2025 05:00 PM ET
▲ +4.06 (1.76%)

This chart shows the closing price for ALNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$234.56Closing price on 04/20/25:
Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

Analyst Price Target is $315.58
▲ +34.54% Upside Potential
This price target is based on 26 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $315.58, with a high forecast of $500.00 and a low forecast of $159.00. The average price target represents a 34.54% upside from the last price of $234.56.

This chart shows the closing price for ALNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$100$200$300$400$500Closing price on 04/20/25: $234.56High$500.00Average$315.58Low$159.00




Current Consensus is Moderate Buy

The current consensus among 26 investment analysts is to moderate buy stock in Alnylam Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2024
  • 0 strong buy ratings
  • 18 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 19 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
1/20/2025
  • 0 strong buy ratings
  • 19 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
3/21/2025
  • 0 strong buy ratings
  • 21 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
4/20/2025

Latest Recommendations

  • 0 strong buy ratings
  • 21 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/11/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$284.00 ➝ $268.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
4/2/2025HC WainwrightReiterated RatingBuy ➝ Buy$500.00 ➝ $500.00
3/31/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$338.00 ➝ $342.00
3/31/2025Redburn AtlanticInitiated CoverageBuy$353.00
3/31/2025Stifel NicolausBoost TargetBuy ➝ Buy$300.00 ➝ $345.00
3/24/2025JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$280.00 ➝ $328.00
3/21/2025CitigroupBoost TargetBuy ➝ Buy$338.00 ➝ $351.00
3/21/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$385.00 ➝ $390.00
3/21/2025Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$310.00 ➝ $330.00
3/21/2025William BlairReiterated RatingOutperform
3/21/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$300.00 ➝ $338.00
3/21/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$275.00 ➝ $287.00
3/21/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
3/21/2025Chardan CapitalReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
3/21/2025Bank of AmericaBoost TargetBuy ➝ Buy$302.00 ➝ $325.00
3/11/2025JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$272.00 ➝ $280.00
2/26/2025William BlairReiterated RatingOutperform
2/26/2025Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$310.00 ➝ $310.00
2/26/2025Chardan CapitalReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
2/26/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
2/24/2025HC WainwrightBoost TargetBuy ➝ Buy$400.00 ➝ $500.00
2/18/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$384.00 ➝ $385.00
2/14/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$310.00 ➝ $300.00
2/14/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$275.00 ➝ $284.00
2/14/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
2/11/2025Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00
1/21/2025Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00
1/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
1/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
1/7/2025Sanford C. BernsteinLower TargetOutperform ➝ Outperform$314.00 ➝ $310.00
11/19/2024William BlairReiterated RatingOutperform
11/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
11/18/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$296.00 ➝ $296.00
11/12/2024Wolfe ResearchDowngradePeer Perform ➝ Underperform
11/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
11/1/2024Raymond JamesBoost TargetOutperform ➝ Outperform$275.00 ➝ $298.00
11/1/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00
11/1/2024BarclaysBoost TargetOverweight ➝ Overweight$295.00 ➝ $329.00
11/1/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$305.00 ➝ $310.00
11/1/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$366.00 ➝ $384.00
11/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
11/1/2024Chardan CapitalReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
10/21/2024TD CowenBoost TargetBuy ➝ Buy$282.00 ➝ $371.00
10/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$305.00
10/14/2024Bank of AmericaBoost TargetBuy ➝ Buy$307.00 ➝ $314.00
10/11/2024Chardan CapitalReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
10/11/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$220.00 ➝ $220.00
10/10/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00
10/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00
9/9/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$220.00 ➝ $220.00
9/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.00
9/4/2024Bank of AmericaBoost TargetBuy ➝ Buy$295.00 ➝ $307.00
8/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
8/26/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$248.00 ➝ $280.00
8/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
8/16/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$198.00 ➝ $370.00
8/2/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$207.00 ➝ $233.00
8/2/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$265.00 ➝ $300.00
8/2/2024Raymond JamesBoost TargetOutperform ➝ Outperform$242.00 ➝ $275.00
8/2/2024CitigroupBoost TargetBuy ➝ Buy$291.00 ➝ $342.00
8/2/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$174.00 ➝ $198.00
8/2/2024BarclaysBoost TargetOverweight ➝ Overweight$291.00 ➝ $295.00
8/2/2024Needham & Company LLCBoost TargetBuy ➝ Buy$275.00 ➝ $320.00
8/2/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$357.00 ➝ $366.00
7/22/2024Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$150.00 ➝ $220.00
7/12/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$250.00 ➝ $255.00
7/8/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$283.00 ➝ $357.00
7/3/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$160.00 ➝ $248.00
7/1/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$150.00 ➝ $150.00
6/28/2024UBS GroupBoost TargetBuy ➝ Buy$253.00 ➝ $288.00
6/27/2024Stifel NicolausBoost TargetBuy ➝ Buy$215.00 ➝ $295.00
6/25/2024CitigroupBoost TargetBuy ➝ Buy$227.00 ➝ $291.00
6/25/2024Bank of AmericaBoost TargetBuy ➝ Buy$248.00 ➝ $295.00
6/25/2024TD CowenBoost TargetBuy ➝ Buy$260.00 ➝ $282.00
6/25/2024Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$138.00 ➝ $159.00
6/25/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$235.00 ➝ $250.00
6/25/2024BarclaysBoost TargetOverweight ➝ Overweight$236.00 ➝ $291.00
6/25/2024Evercore ISIBoost TargetOutperform ➝ Outperform$210.00 ➝ $260.00
6/25/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$161.00 ➝ $207.00
6/25/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$164.00 ➝ $250.00
6/24/2024Needham & Company LLCBoost TargetBuy ➝ Buy$200.00 ➝ $275.00
6/24/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$234.00 ➝ $234.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
6/21/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$283.00 ➝ $283.00
5/7/2024HC WainwrightBoost TargetBuy ➝ Buy$395.00 ➝ $400.00
5/3/2024Chardan CapitalReiterated RatingBuy ➝ Buy$225.00 ➝ $225.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$200.00
4/8/2024William BlairReiterated RatingOutperform
3/27/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$234.00
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$395.00
2/20/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00
2/20/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$235.00
2/16/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$171.00 ➝ $161.00
2/16/2024CitigroupLower TargetBuy ➝ Buy$237.00 ➝ $227.00
2/16/2024Chardan CapitalLower TargetBuy ➝ Buy$250.00 ➝ $225.00
2/16/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$230.00 ➝ $173.00
2/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$200.00
2/15/2024Wolfe ResearchInitiated CoveragePeer Perform
2/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$235.00
2/13/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$184.00 ➝ $176.00
2/12/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00
2/1/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$150.00 ➝ $170.00
1/18/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00
1/8/2024William BlairReiterated RatingOutperform
12/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$395.00
12/14/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00
12/14/2023Piper SandlerBoost TargetOverweight ➝ Overweight$210.00 ➝ $217.00
12/8/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$171.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$395.00
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$235.00 ➝ $230.00
11/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$175.00 ➝ $183.00
10/16/2023Cantor FitzgeraldLower TargetNeutral ➝ Neutral$190.00 ➝ $170.00
10/11/2023OppenheimerDowngradeOutperform ➝ Market Perform
10/11/2023Royal Bank of CanadaLower Target$270.00 ➝ $235.00
10/11/2023HC WainwrightLower TargetBuy ➝ Buy$405.00 ➝ $395.00
10/10/2023Sanford C. BernsteinLower Target$237.00 ➝ $218.00
10/10/2023Evercore ISILower Target$252.00 ➝ $210.00
10/10/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$250.00 ➝ $234.00
10/10/2023CitigroupLower TargetBuy ➝ Buy$266.00 ➝ $233.00
10/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$210.00 ➝ $175.00
10/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$240.00 ➝ $200.00
10/6/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00
9/28/2023Raymond JamesInitiated CoverageOutperform$208.00
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$405.00
9/14/2023Stifel NicolausReiterated RatingBuy ➝ Buy$240.00
9/14/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$190.00
9/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$240.00
9/12/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00
8/28/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00
8/18/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00
8/16/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$190.00
8/8/2023Chardan CapitalReiterated RatingBuy ➝ Buy$250.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$405.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$210.00
8/4/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$240.00
8/4/2023CitigroupBoost TargetBuy ➝ Buy$265.00 ➝ $266.00
7/26/2023Sanford C. BernsteinLower Target$247.00 ➝ $233.00
7/25/2023William BlairReiterated RatingOutperform
7/25/2023Royal Bank of CanadaLower TargetOutperform$275.00 ➝ $270.00
7/25/2023HC WainwrightLower TargetBuy$415.00 ➝ $405.00
5/5/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$200.00 ➝ $250.00
4/26/2023Sumitomo Mitsui Financial GroupInitiated CoverageNeutral$220.00
4/4/2023Morgan StanleyBoost TargetEqual Weight$205.00 ➝ $210.00
3/21/2023Sanford C. BernsteinInitiated CoverageOutperform$243.00
3/3/2023JPMorgan Chase & Co.Lower TargetNeutral$200.00 ➝ $196.00
3/3/2023HC WainwrightReiterated RatingBuy$415.00
2/24/2023Needham & Company LLCReiterated RatingBuy$240.00
2/24/2023Chardan CapitalReiterated RatingBuy$250.00
2/24/2023OppenheimerLower TargetOutperform$256.00 ➝ $249.00
2/24/2023Morgan StanleyLower TargetEqual Weight$210.00 ➝ $205.00
2/24/2023Canaccord Genuity GroupLower TargetBuy$310.00 ➝ $291.00
2/24/2023CitigroupLower TargetBuy$270.00 ➝ $265.00
2/21/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$304.00
1/23/2023Leerink PartnersLower TargetMarket Perform$144.00 ➝ $143.00
1/18/2023Canaccord Genuity GroupInitiated CoverageBuy$310.00
12/16/2022Piper SandlerBoost TargetOverweight$226.00 ➝ $253.00
11/7/2022Leerink PartnersBoost TargetMarket Perform$142.00 ➝ $145.00
11/2/2022HC WainwrightLower TargetBuy$430.00 ➝ $415.00
10/28/2022BarclaysLower TargetOverweight$240.00 ➝ $236.00
10/28/2022Morgan StanleyLower TargetEqual Weight$220.00 ➝ $210.00
10/28/2022The Goldman Sachs GroupBoost TargetBuy$239.00 ➝ $270.00
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$204.00 ➝ $200.00
10/13/2022Morgan StanleyLower TargetEqual Weight$222.00 ➝ $220.00
10/3/2022Jefferies Financial GroupBoost TargetBuy$218.00 ➝ $232.00
9/20/2022Royal Bank of CanadaBoost TargetOutperform$225.00 ➝ $250.00
9/9/2022Morgan StanleyReiterated RatingEqual Weight$225.00 ➝ $222.00
9/9/2022BMO Capital MarketsBoost TargetMarket Perform$192.00 ➝ $200.00
9/9/2022OppenheimerBoost TargetOutperform$170.00 ➝ $256.00
8/9/2022Evercore ISIBoost Target$252.00
8/4/2022BMO Capital MarketsBoost TargetMarket Perform$166.00 ➝ $192.00
8/4/2022Morgan StanleyBoost TargetEqual Weight$159.00 ➝ $225.00
8/4/2022Chardan CapitalBoost TargetBuy$200.00 ➝ $250.00
8/4/2022Needham & Company LLCBoost TargetBuy$205.00 ➝ $240.00
8/4/2022CitigroupBoost Target$206.00 ➝ $280.00
7/29/2022Morgan StanleyLower TargetEqual Weight$164.00 ➝ $159.00
7/29/2022CitigroupLower Target$211.00 ➝ $206.00
7/15/2022Morgan StanleyLower TargetEqual Weight$170.00 ➝ $164.00
7/12/2022Cantor FitzgeraldInitiated CoverageNeutral$175.00
6/27/2022GuggenheimDowngradeBuy ➝ Neutral
6/16/2022Needham & Company LLCInitiated CoverageBuy$205.00
6/15/2022Leerink PartnersBoost TargetMarket Perform$96.00 ➝ $98.00
6/7/2022William BlairInitiated CoverageOutperform
5/2/2022HC WainwrightBoost Target$400.00 ➝ $430.00
4/29/2022CitigroupLower Target$223.00 ➝ $211.00
4/25/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$210.00 ➝ $178.00
4/12/2022HC WainwrightBoost TargetBuy$350.00 ➝ $400.00
4/6/2022OppenheimerReiterated RatingOutperform$205.00
3/24/2022Stifel NicolausReiterated RatingBuy$215.00
2/28/2022CitigroupInitiated CoverageBuy$223.00
2/23/2022Morgan StanleyLower TargetOverweight$215.00 ➝ $210.00
2/11/2022Chardan CapitalReiterated RatingBuy$200.00
2/11/2022Leerink PartnersLower TargetMarket Perform$109.00 ➝ $103.00
2/3/2022GuggenheimUpgradeNeutral ➝ Buy$170.00
1/28/2022Leerink PartnersBoost TargetMarket Perform$108.00 ➝ $109.00
1/20/2022HC WainwrightBoost TargetBuy$250.00 ➝ $350.00
1/18/2022Morgan StanleyLower TargetOverweight$226.00 ➝ $215.00
1/3/2022Bank of AmericaReiterated RatingBuy ➝ Buy$211.00
1/3/2022Piper SandlerUpgradeNeutral ➝ Overweight$181.00 ➝ $208.00
12/30/2021OppenheimerReiterated RatingOutperform$200.00
12/1/2021Leerink PartnersReiterated RatingHold
11/22/2021Needham & Company LLCBoost TargetBuy$180.00 ➝ $205.00
11/22/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$273.00
11/22/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$144.00 ➝ $225.00
11/1/2021OppenheimerUpgradeMarket Perform ➝ Outperform$200.00
10/31/2021BMO Capital MarketsReiterated RatingHold ➝ Neutral
10/29/2021Morgan StanleyLower TargetOverweight$242.00 ➝ $226.00
10/29/2021Chardan CapitalBoost TargetBuy$190.00 ➝ $200.00
10/29/2021Cantor FitzgeraldBoost TargetOverweight$202.00 ➝ $275.00
10/28/2021Leerink PartnersBoost TargetMarket Perform$104.00 ➝ $108.00
10/18/2021Leerink PartnersReiterated RatingMarket Perform
10/12/2021Morgan StanleyBoost TargetOverweight$234.00 ➝ $242.00
10/4/2021UBS GroupUpgradeNeutral ➝ Buy$141.00 ➝ $215.00
8/27/2021BMO Capital MarketsBoost TargetNeutral ➝ Market Perform$174.00 ➝ $196.00
8/13/2021HC WainwrightBoost TargetBuy$235.00 ➝ $250.00
8/4/2021Chardan CapitalReiterated RatingBuy$190.00
8/4/2021Morgan StanleyBoost TargetOverweight$224.00 ➝ $234.00
8/4/2021BarclaysBoost TargetOverweight$196.00 ➝ $216.00
8/4/2021Piper SandlerDowngradeOverweight ➝ Neutral$45.00 ➝ $47.00
7/16/2021Morgan StanleyBoost TargetOverweight$205.00 ➝ $224.00
4/30/2021Morgan StanleyLower TargetOverweight$206.00 ➝ $205.00
4/20/2021Needham & Company LLCReiterated RatingBuy
3/1/2021GuggenheimReiterated RatingBuy ➝ Neutral$162.00
2/22/2021GuggenheimDowngradeBuy ➝ Neutral$162.00
2/14/2021Royal Bank of CanadaReiterated RatingHold
2/12/2021Needham & Company LLCBoost TargetBuy$160.00 ➝ $180.00
2/12/2021Morgan StanleyBoost TargetOverweight$203.00 ➝ $206.00
2/12/2021CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $175.00
2/12/2021BarclaysBoost TargetOverweight$162.00 ➝ $196.00
2/12/2021HC WainwrightBoost TargetBuy$225.00 ➝ $235.00
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$185.00 ➝ $185.00
1/13/2021CowenBoost TargetIn-Line ➝ Outperform$154.00 ➝ $197.00
1/8/2021HC WainwrightReiterated RatingBuy$225.00
12/21/2020Royal Bank of CanadaLower TargetSector Perform$150.00 ➝ $144.00
12/17/2020Piper SandlerBoost TargetOverweight$169.00 ➝ $181.00
11/25/2020BMO Capital MarketsBoost Target$182.00 ➝ $183.00
11/25/2020Morgan StanleyBoost TargetOverweight$200.00 ➝ $203.00
11/24/2020Leerink PartnersBoost TargetMarket Perform$90.00 ➝ $91.00
11/6/2020Morgan StanleyBoost TargetOverweight$197.00 ➝ $200.00
10/15/2020Bank of AmericaLower TargetBuy$160.00 ➝ $157.00
10/12/2020Chardan CapitalReiterated RatingBuy
9/30/2020OppenheimerReiterated RatingHold$156.00
9/30/2020Berenberg BankInitiated CoverageHold$145.00
9/8/2020CitigroupInitiated CoverageBuy$170.00 ➝ $170.00
8/24/2020HC WainwrightReiterated RatingBuy
8/11/2020OppenheimerDowngradeOutperform ➝ Market Perform$162.00 ➝ $156.00
8/7/2020Morgan StanleyLower TargetOverweight$199.00 ➝ $197.00
8/7/2020Chardan CapitalReiterated RatingBuy
8/7/2020Leerink PartnersBoost TargetMarket Perform$89.00 ➝ $90.00
7/20/2020BMO Capital MarketsBoost TargetOutperform$173.00 ➝ $196.00
7/15/2020Morgan StanleyBoost TargetOverweight$162.00 ➝ $199.00
5/28/2020UBS GroupBoost TargetNeutral$111.00 ➝ $122.00
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$150.00
5/7/2020BMO Capital MarketsBoost TargetOutperform$145.00 ➝ $171.00
5/7/2020OppenheimerBoost TargetOutperform$140.00 ➝ $162.00
5/7/2020Morgan StanleyBoost TargetOverweight$148.00 ➝ $162.00
5/7/2020BarclaysBoost TargetOverweight$143.00 ➝ $156.00
5/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00
5/6/2020Needham & Company LLCBoost TargetBuy$135.00 ➝ $160.00
4/24/2020Evercore ISIInitiated CoverageBuy$160.00
(Data available from 4/21/2020 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 29 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 24 very positive mentions
  • 34 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 34 very positive mentions
  • 30 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 44 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024
  • 16 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025
  • 49 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2025
  • 45 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2025
  • 78 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2025

Current Sentiment

  • 78 very positive mentions
  • 33 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $234.56
Low: $228.96
High: $235.12

50 Day Range

MA: $249.14
Low: $224.32
High: $290.70

52 Week Range

Now: $234.56
Low: $141.98
High: $304.39

Volume

601,349 shs

Average Volume

869,185 shs

Market Capitalization

$30.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Redburn Atlantic, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for ALNY.

What is the current price target for Alnylam Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $315.58, suggesting a possible upside of 34.5%. HC Wainwright has the highest price target set, predicting ALNY will reach $500.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $159.00 for Alnylam Pharmaceuticals in the next year.
View the latest price targets for ALNY.

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals currently has 1 sell rating, 4 hold ratings and 21 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALNY.

What other companies compete with Alnylam Pharmaceuticals?

Other companies that are similar to Alnylam Pharmaceuticals include Regeneron Pharmaceuticals, Biogen, United Therapeutics, Incyte and BioMarin Pharmaceutical. Learn More about companies similar to Alnylam Pharmaceuticals.

How do I contact Alnylam Pharmaceuticals' investor relations team?

Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 551-8200 and its investor relations email address is investors@alnylam.com. The official website for Alnylam Pharmaceuticals is www.alnylam.com. Learn More about contacing Alnylam Pharmaceuticals investor relations.